{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:58:34Z","timestamp":1790686714010,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40262-026-01695-5","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:06:07Z","timestamp":1788541567000},"page":"1591-1612","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Pharmacokinetics and Pharmacodynamics of Marstacimab, an Anti-tissue Factor Pathway Inhibitor Monoclonal Antibody, in Adolescent and Adult Participants with Hemophilia"],"prefix":"10.1007","volume":"65","clinical-trial-number":[{"clinical-trial-number":"nct02531815","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02974855","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03363321","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03938792","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04832139","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04878731","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Satyaprakash","family":"Nayak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyuki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patanjali","family":"Ravva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta","family":"Raje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"issue":"4","key":"1695_CR1","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3109\/10409238.2015.1050550","volume":"50","author":"SA Smith","year":"2015","unstructured":"Smith SA, Travers RJ, Morrissey JH. How it all starts: initiation of the clotting cascade. Crit Rev Biochem Mol Biol. 2015;50(4):326\u201336.","journal-title":"Crit Rev Biochem Mol Biol"},{"issue":"Suppl 6","key":"1695_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","volume":"26","author":"A Srivastava","year":"2020","unstructured":"Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1\u2013158.","journal-title":"Haemophilia"},{"issue":"9","key":"1695_CR3","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.3324\/haematol.2019.221093","volume":"104","author":"G Castaman","year":"2019","unstructured":"Castaman G, Matino D. Hemophilia A and B: molecular and clinical similarities and differences. Haematologica. 2019;104(9):1702\u20139.","journal-title":"Haematologica"},{"issue":"1","key":"1695_CR4","doi-asserted-by":"publisher","first-page":"262","DOI":"10.2741\/3926","volume":"17","author":"GJ Broze Jr","year":"2012","unstructured":"Broze GJ Jr, Girard TJ. Tissue factor pathway inhibitor: structure-function. Front Biosci (Landmark Ed). 2012;17(1):262\u201380.","journal-title":"Front Biosci (Landmark Ed)."},{"issue":"Suppl 2","key":"1695_CR5","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/S0049-3848(16)30359-0","volume":"141","author":"JA Peterson","year":"2016","unstructured":"Peterson JA, Maroney SA, Mast AE. Targeting TFPI for hemophilia treatment. Thromb Res. 2016;141(Suppl 2):S28-30.","journal-title":"Thromb Res"},{"issue":"2","key":"1695_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12679","volume":"6","author":"DD Pittman","year":"2022","unstructured":"Pittman DD, Rakhe S, Bowley SR, et al. Hemostatic efficacy of marstacimab alone or in combination with bypassing agents in hemophilia plasmas and a mouse bleeding model. Res Pract Thromb Haemost. 2022;6(2):e12679.","journal-title":"Res Pract Thromb Haemost"},{"key":"1695_CR7","unstructured":"US Food and Drug Administration. Hympavzi (marstacimab-hncq) prescribing information 2026 [cited 2026 August]. Available from: https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=20916"},{"key":"1695_CR8","unstructured":"European Medicines Agency. Hympavzi: EPAR\u2014product information 2026 [cited 2026 August]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/hympavzi."},{"issue":"9","key":"1695_CR9","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1111\/jth.14207","volume":"16","author":"M Cardinal","year":"2018","unstructured":"Cardinal M, Kantaridis C, Zhu T, et al. A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers. J Thromb Haemost. 2018;16(9):1722\u201331.","journal-title":"J Thromb Haemost"},{"key":"1695_CR10","first-page":"41","volume":"28","author":"S Raje","year":"2022","unstructured":"Raje S, Plotka A, Huyghe I, et al. Bioequivalence (BE) of marstacimab prefilled pen (PFP) device and prefilled syringe (PFS) device following subcutaneous (SC) administration in healthy adult males. Haemophilia. 2022;28:41\u20132.","journal-title":"Haemophilia"},{"issue":"4","key":"1695_CR11","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1111\/hae.14814","volume":"29","author":"X Sun","year":"2023","unstructured":"Sun X, Liu W, Luo B, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of marstacimab in Chinese participants with severe haemophilia. Haemophilia. 2023;29(4):1155\u20139.","journal-title":"Haemophilia"},{"issue":"2","key":"1695_CR12","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/bjh.18420","volume":"200","author":"JN Mahlangu","year":"2023","unstructured":"Mahlangu JN, Lamas JL, Morales JC, et al. A phase 1b\/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia. Br J Haematol. 2023;200(2):229\u201339.","journal-title":"Br J Haematol"},{"issue":"2","key":"1695_CR13","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/bjh.18495","volume":"200","author":"J Mahlangu","year":"2023","unstructured":"Mahlangu J, Luis Lamas J, Cristobal Morales J, et al. Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: phase II study results. Br J Haematol. 2023;200(2):240\u20138.","journal-title":"Br J Haematol"},{"issue":"14","key":"1695_CR14","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1182\/blood.2024027468","volume":"146","author":"D Matino","year":"2025","unstructured":"Matino D, Palladino A, Taylor CT, et al. Marstacimab prophylaxis in hemophilia A\/B without inhibitors: results from the phase 3 basis trial. Blood. 2025;146(14):1654\u201363.","journal-title":"Blood"},{"key":"1695_CR15","doi-asserted-by":"crossref","unstructured":"Parng C, Jin M, Holsti M, et al. In vitro and in vivo characterization of marstacimab, an anti-TFPI antibody. Blood. 2019;134(Suppl 1):2391.","DOI":"10.1182\/blood-2019-130327"},{"key":"1695_CR16","unstructured":"US Department of Health and Human Services FDA. Population pharmacokinetics: guidance for industry 2022 [cited 2026 August]. https:\/\/www.fda.gov\/media\/128793\/download."},{"key":"1695_CR17","unstructured":"United States Centers for Disease Control and Prevention. Clinical growth charts 2000 [cited 2026 August]. Available from: https:\/\/www.cdc.gov\/growthcharts\/clinical_charts.htm."},{"issue":"9","key":"1695_CR18","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/psp4.12224","volume":"6","author":"JT Ryman","year":"2017","unstructured":"Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacomet Syst Pharmacol. 2017;6(9):576\u201388.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"3","key":"1695_CR19","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/cpt.3150","volume":"115","author":"JD Davis","year":"2024","unstructured":"Davis JD, Bravo Padros M, Conrado DJ, et al. Subcutaneous administration of monoclonal antibodies: pharmacology, delivery, immunogenicity, and learnings from applications to clinical development. Clin Pharmacol Ther. 2024;115(3):422\u201339.","journal-title":"Clin Pharmacol Ther"},{"issue":"Supplement 1","key":"1695_CR20","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1182\/blood-2024-199766","volume":"144","author":"S Nayak","year":"2024","unstructured":"Nayak S, Suzuki A, Ravva P, et al. A fixed (weight-independent) subcutaneous once-weekly dose for marstacimab, an anti-TFPI monoclonal antibody for the prophylactic treatment of hemophilia A and B. Blood. 2024;144(Suppl 1):1215.","journal-title":"Blood"},{"issue":"1","key":"1695_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2005.12.041","volume":"72","author":"DE Mager","year":"2006","unstructured":"Mager DE. Target-mediated drug disposition and dynamics. Biochem Pharmacol. 2006;72(1):1\u201310.","journal-title":"Biochem Pharmacol"},{"key":"1695_CR22","first-page":"PB0240","volume":"4","author":"J Apgar","year":"2020","unstructured":"Apgar J, Parng C, Benard S, et al. X-ray crystallography and hemostatic activities of a neutralizing anti-TFPI antibody, marstacimab. Res Pract Thromb Haemost. 2020;4:PB0240.","journal-title":"Res Pract Thromb Haemost"},{"issue":"24","key":"1695_CR23","doi-asserted-by":"publisher","first-page":"5871","DOI":"10.1182\/blood-2012-01-401620","volume":"119","author":"I Hilden","year":"2012","unstructured":"Hilden I, Lauritzen B, Sorensen BB, et al. Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model. Blood. 2012;119(24):5871\u20138.","journal-title":"Blood"},{"key":"1695_CR24","doi-asserted-by":"crossref","unstructured":"Bauzon M, Liu B, Grudzinska-Goebel J, et al. Characterization of a high-affinity fully human IgG2 antibody against tissue factor pathway inhibitor as a bypass agent for the treatment of hemophilia. Blood 2015;126(23):3513","DOI":"10.1182\/blood.V126.23.3513.3513"},{"key":"1695_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.670526","volume":"8","author":"JN Mahlangu","year":"2021","unstructured":"Mahlangu JN. Progress in the development of anti-tissue factor pathway inhibitors for haemophilia management. Front Med (Lausanne). 2021;8:670526.","journal-title":"Front Med (Lausanne)."},{"key":"1695_CR26","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.addr.2020.05.009","volume":"167","author":"M Sanchez-Felix","year":"2020","unstructured":"Sanchez-Felix M, Burke M, Chen HH, et al. Predicting bioavailability of monoclonal antibodies after subcutaneous administration: open innovation challenge. Adv Drug Deliv Rev. 2020;167:66\u201377.","journal-title":"Adv Drug Deliv Rev"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01695-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01695-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01695-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:20:03Z","timestamp":1790684403000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01695-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1695"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01695-5","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"assertion":[{"value":"18 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Satyaprakash Nayak, Akiyuki Suzuki, Patanjali Ravva, and Sangeeta Raje are employees of Pfizer and may own stock or stock options.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All 6 studies were approved by institutional review boards or ethics committees according to the requirements of the specific countries of origin.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided written informed consent prior to initiation of study medications.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions, and exceptions, Pfizer may also provide access to the related individual de-identified participant data. See\u00a0\n                      \n                      for more information.","order":5,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors participated in data interpretation and critical review and revision of this manuscript and provided approval of the manuscript for submission.","order":7,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}